BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37959743)

  • 1. Design, Synthesis, and Antiproliferative Activity of Selective Histone Deacetylases 6 Inhibitors Containing a Tetrahydropyridopyrimidine Scaffold.
    Wang B; Liu Y; Zhang L; Wang Y; Li Z; Chen X
    Molecules; 2023 Oct; 28(21):. PubMed ID: 37959743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
    Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
    Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
    Xu X; Zhang D; Zhao T; Wang M; Li Y; Du Q; Kou J; Li Z; Bian J
    Eur J Med Chem; 2022 Apr; 233():114228. PubMed ID: 35245830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.
    Khetmalis YM; Fathima A; Schweipert M; Debarnot C; Bandaru NVMR; Murugesan S; Jamma T; Meyer-Almes FJ; Sekhar KVGC
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
    Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
    Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 2-quinolineacrylamides.
    Wang SW; Lin MH; Hsu FC; Chen MC; Liou JP; Liu YT; Chen SS; Lee HY
    Bioorg Med Chem; 2020 Feb; 28(3):115250. PubMed ID: 31924504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.
    Bui HTB; Nguyen PH; Pham QM; Tran HP; Tran Q; Jung H; Hong QV; Nguyen QC; Nguyen QP; Le HT; Yang SG
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
    Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
    J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
    Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
    Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity.
    Chen X; Wang J; Zhao P; Dang B; Liang T; Steimbach RR; Miller AK; Liu J; Wang X; Zhang T; Luan X; Hu J; Gao J
    Eur J Med Chem; 2023 Nov; 260():115776. PubMed ID: 37660484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
    Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
    Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.